Your browser doesn't support javascript.
loading
Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.
Doobaree, Indraraj Umesh; Newland, Adrian; McDonald, Vickie; Nandigam, Raghava; Mensah, Lesley; Leroy, Sandrine; Seesaghur, Anouchka; Patel, Hitan; Wetten, Sally; Provan, Drew.
Afiliação
  • Doobaree IU; Barts and The London School of Medicine and Dentistry, London, UK.
  • Newland A; Barts and The London School of Medicine and Dentistry, London, UK.
  • McDonald V; Barts and The London School of Medicine and Dentistry, London, UK.
  • Nandigam R; Barts and The London School of Medicine and Dentistry, London, UK.
  • Mensah L; Amgen Limited, London, UK.
  • Leroy S; Center for Observational Research, Amgen Limited, London, UK.
  • Seesaghur A; Center for Observational Research, Amgen Limited, London, UK.
  • Patel H; Amgen Limited, Cambridge, UK.
  • Wetten S; Amgen Limited, London, UK.
  • Provan D; Barts and The London School of Medicine and Dentistry, London, UK.
Eur J Haematol ; 102(5): 416-423, 2019 May.
Article em En | MEDLINE | ID: mdl-30758874
ABSTRACT

BACKGROUND:

Romiplostim is a thrombopoietin-mimetic peptibody for adult refractory chronic immune thrombocytopenia (ITP). We aimed to describe ITP patients receiving romiplostim, platelet counts and romiplostim usage in UK clinical practice.

METHODS:

This was a retrospective cohort study of patients in the UKITP Registry who received romiplostim between October 2009 and January 2015, including data up to 6 months before romiplostim initiation through follow-up.

RESULTS:

Of 1440 patients in the UKITP Registry, 118 adults with primary ITP were eligible. Before romiplostim, 22% had splenectomy, 12% received platelet transfusion, 97% received ≥ 1 different ITP medication and 77% received ≥ 3. Most patients (73%) initiated romiplostim ≥ 1 year after ITP diagnosis (chronic phase). The mean duration of romiplostim treatment was 5.7 (SE 0.9) months, and the median was 1.4 months (IQR 0.2, 6.5). Mean platelet count before romiplostim was 38 × 109 /L, rising to 103 × 109 /L within 1 month, and remaining 50-150 × 109 /L through up to 3 years of follow-up. After romiplostim, 4% of patients had splenectomy, 6% received platelet transfusion, and 57% received just one ITP medication other than romiplostim.

CONCLUSION:

The study provides valuable insights into the real-world use of romiplostim in primary ITP in routine practice and highlighted the timing of romiplostim initiation at different ITP disease phases.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombopoetina / Proteínas Recombinantes de Fusão / Receptores Fc / Púrpura Trombocitopênica Idiopática Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Eur J Haematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombopoetina / Proteínas Recombinantes de Fusão / Receptores Fc / Púrpura Trombocitopênica Idiopática Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Eur J Haematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido